CHIA-LIN HSUKUAN-YU CHENSHUENN-WEN KUOYIH-LEONG CHANG2021-04-292021-04-2920171556-0864https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019373716&doi=10.1016%2fj.jtho.2017.02.006&partnerID=40&md5=f23756a236de18ab66633fd55777bfc4https://scholars.lib.ntu.edu.tw/handle/123456789/558193[SDGs]SDG3anaplastic lymphoma kinase; cytokeratin 7; docetaxel; epidermal growth factor receptor; pembrolizumab; pemetrexed; programmed death 1 ligand 1; protein p40; thyroid transcription factor 1; vimentin; vinorelbine tartrate; immunological antineoplastic agent; monoclonal antibody; pembrolizumab; aged; ALK gene; cancer chemotherapy; cancer growth; cancer radiotherapy; case report; computer assisted tomography; drug efficacy; drug safety; dyspnea; EGFR gene; follow up; gene mutation; gene translocation; human; human tissue; Letter; lung biopsy; lymphadenopathy; male; mediastinum lymphadenopathy; multiple cycle treatment; non small cell lung cancer; pleura effusion; priority journal; protein expression; supraclavicular lymphadenopathy; treatment response; adenocarcinoma; chemically induced; lung tumor; non small cell lung cancer; pathology; prognosis; squamous cell carcinoma; Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Male; Prognosisletter10.1016/j.jtho.2017.02.006285325672-s2.0-85019373716